Andrew Macintyre is a bioanalytical executive with over 20 years of experience directing global clinical and preclinical programs for CROs and pharmaceutical companies. He specializes in GLP bioanalysis—including LC-MS, flow cytometry, and immunoassays—regulatory submissions for the FDA and EMA, and CRO governance.

With a proven track record in oncology, immunology, and CNS trials, Andrew has extensive experience in study start-up and complex biomarker studies. He currently leads clinical operations at GLSA and advises biotech clients on bioanalytical strategy, assay validation, and inspection readiness. His expertise also extends to AI-enabled trial tools, lab automation, and comparator sourcing.